Table 2 Patient characteristics of the propensity score-matched cohort
SABR (n = 49) | CFRT (n = 49) | |||
|---|---|---|---|---|
Variable | No. of patients (%) | No. of patients (%) | p-value | SMD |
Time of treatment | 0.840 | 0.041 | ||
Before December 31, 2011 | 24 (49.0) | 23 (46.9) | ||
After December 31, 2011 | 25 (51.0) | 26 (53.1) | ||
Age, year | 0.648 | 0.082 | ||
Mean (SD)*, range | 60.2 (13.2), 32–84 | 59.1 (10.9), 34–78 | ||
≤ 60 | 22 (44.9) | 24 (49.0) | ||
> 60 | 27 (55.1) | 25 (51.0) | ||
Sex | 0.812 | 0.048 | ||
Male | 38 (77.6) | 37 (75.5) | ||
Female | 11 (22.4) | 12 (24.5) | ||
Liver disease | 0.259 | 0.116 | ||
HBV | 28 (57.1) | 32 (65.3) | ||
HCV | 14 (28.6) | 7 (14.3) | ||
HBV and HCV | 1 (2.0) | 3 (6.1) | ||
Non-virus | 6 (12.2) | 7 (14.3) | ||
ECOG | 0.790 | 0.054 | ||
0–1 | 41 (83.7) | 40 (81.6) | ||
2 | 8 (16.3) | 9 (18.4) | ||
Extrahepatic metastasis | 1.000 | < 0.001 | ||
Yes | 5 (10.2) | 5 (10.2) | ||
No | 44 (89.8) | 44 (89.8) | ||
AFP, ng/ml | 0.541 | 0.124 | ||
≤200 | 20 (40.8) | 23 (46.9) | ||
> 200 | 29 (59.2) | 26 (53.1) | ||
Child-Pugh class | 0.835 | 0.042 | ||
A | 31 (63.3) | 30 (61.2) | ||
B | 18 (36.7) | 19 (38.8) | ||
Prior treatment | ||||
Yes | 25 (51.0) | 28 (57.1) | 0.543 | 0.123 |
No | 24 (49.0) | 21 (42.9) | ||
No. of tumor | 0.828 | 0.044 | ||
Multiple | 34 (69.4) | 33 (67.3) | ||
Single | 15 (30.6) | 16 (32.7) | ||
Tumor size, cm | 1.000 | < 0.001 | ||
≤8 | 24 (49.0) | 24 (49.0) | ||
> 8 | 25 (51.0) | 25 (51.0) | ||
PVI location | 1.000 | < 0.001 | ||
Vp4 | 21 (42.9) | 21 (42.9) | ||
Vp3 | 28 (57.1) | 28 (57.1) | ||
Sorafenib | 1.000 | < 0.001 | ||
Yes | 21 (42.9) | 21 (42.9) | ||
No | 28 (57.1) | 28 (57.1) | ||
BED, Gy | < 0.001 | 1.124 | ||
< 65 | 13 (26.5) | 37 (75.5) | ||
≥ 65 | 36 (73.5) | 12 (24.5) |